Monte Rosa’s AI-driven insights are significantly expanding the universe of targetable proteins for molecular glue degraders, opening up new avenues to tackle previously “undruggable” therapeutic targets.
BOSTON, July 3, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology firm pioneering novel molecular glue degrader (MGD) medicines, today unveiled groundbreaking discoveries featured on the cover of the prestigious journal Science. The research marks a significant advancement, detailing how Monte Rosa’s proprietary artificial intelligence (AI) and machine learning (ML) engine has identified a vast landscape of human proteins potentially susceptible to degradation via cereblon (CRBN). This broadens the spectrum of actionable targets for MGD drug discovery across diverse protein domains and classes.
“These findings, highlighted on the cover of Science, are a testament to our QuEEN™ discovery engine’s power, accelerating our mission to develop first-in-class medicines for historically challenging targets,” stated Dr. Sharon Townson, Chief Scientific Officer at Monte Rosa. “We are already integrating these insights to advance our rapidly growing pipeline of differentiated MGDs, creating future medicines with the potential to truly transform patient outcomes.”
“Our innovative approach to MGD discovery seamlessly integrates proprietary datasets with advanced geometric deep learning to meticulously characterize protein surfaces,” explained Dr. John Castle, Chief Data and Information Officer at Monte Rosa. “This has allowed us to uncover new principles of interaction between protein targets, small molecules, and E3 ligases like cereblon. We’re actively leveraging these insights with our QuEEN discovery engine to design highly selective degrader therapies with precision. This work not only underscores cereblon’s adaptability but also demonstrates our capability to design MGDs that can effectively target previously inaccessible, disease-relevant proteins.”
Monte Rosa’s QuEEN discovery engine employs custom-built AI/ML algorithms to analyze protein surfaces at an unprecedented scale. This process uncovers novel surfaces capable of recruiting cereblon for targeted protein degradation, thereby dramatically expanding the reach of MGDs and redefining the criteria for molecular glue-induced target engagement. The research paper further elaborates on Monte Rosa’s proprietary AI and ML methodologies, including the use of geometric deep learning to map protein surface features and project them across the proteome, identifying complementary structures essential for mediating protein-protein interactions. This comprehensive analysis has successfully identified numerous new protein targets amenable to Monte Rosa’s drug discovery strategy, spanning over 100 target classes, many of which are currently considered beyond the reach of conventional small molecule approaches. These pivotal findings significantly enhance Monte Rosa’s potential therapeutic impact in critical areas such as immunology, inflammation, and oncology, where the company currently has active clinical programs.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing highly selective molecular glue degrader (MGD) medicines for patients facing serious conditions across oncology, autoimmune and inflammatory diseases, and beyond. MGDs represent a promising modality, offering the potential to address diseases that remain intractable to other therapeutic approaches, including other types of degraders. Monte Rosa’s proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine uniquely combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to enable the rational design of MGDs with exceptional selectivity. The company proudly hosts the industry’s leading MGD pipeline, with programs targeting autoimmune and inflammatory diseases, oncology, and other therapeutic areas. Monte Rosa has established a global licensing agreement with Novartis for the advancement of VAV1-directed molecular glue degraders and a strategic collaboration with Roche focused on discovering and developing MGDs against targets in cancer and neurological diseases previously deemed undruggable.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/3945.html
